Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.4% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares traded down 7.4% during trading on Wednesday . The stock traded as low as $29.20 and last traded at $29.67. 173,272 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 1,041,596 shares. The stock had previously closed at $32.05.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The firm’s fifty day moving average price is $23.55 and its two-hundred day moving average price is $17.73.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in Regencell Bioscience in the 3rd quarter worth approximately $598,000. Squarepoint Ops LLC bought a new stake in shares of Regencell Bioscience during the 2nd quarter worth $1,701,000. BNP Paribas Financial Markets purchased a new position in Regencell Bioscience in the second quarter worth $768,000. Geode Capital Management LLC boosted its holdings in shares of Regencell Bioscience by 5,637.5% in the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after purchasing an additional 384,250 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Regencell Bioscience during the 2nd quarter valued at about $222,000. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.